



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Antonio Gonzalez (Spain)  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editor**  
Ane Gerda Zahl Eriksson (Norway)

**Managing Editor**  
Lindsey Struckmeyer (USA)

**Editorial Office**  
*International Journal of Gynecological Cancer*, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jgeditorial.com](mailto:ijgc@jgeditorial.com)

**Production Editor**  
Michaela Joseph  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](mailto:support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/products/services/  
rights-and-licensing/](http://bmj.com/company/products/services/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

The *International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Lead article

- 409** Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin  
*L L Lin, D S Lakomy, M S Ning, F Simpkins, A Jhingran*

## Editorials

- 424** Innovation abounds in cancer therapy  
*R L Coleman*
- 426** World Health Organization call for action to eliminate cervical cancer globally  
*M Gultekin, P T Ramirez, N Broutet, R Hutubessy*

## Joint statement

- 428** European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis  
*M Rees, R Angioli, R L Coleman, R M Glasspool, F Plotti, T Simoncini, C Terranova*

## Society statement

- 434** ESGO contribution to the WHO initiative on elimination of cervical cancer  
*M Gultekin, P Morice, N Concin, D Querleu*
- 436** Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update  
*C Fotopoulou, N Concin, F Planchamp, P Morice, I Vergote, A du Bois, D Querleu*

## Meeting summary

- 441** Report from the 21st meeting of the European Society of Gynaecological Oncology (ESGO 2019)  
*N Bizzarri, Z Razumova, I Selcuk, N Taumberger, T Nikolova, C Fotopoulou, E Van der Steen-Banasik, A Ferrero, K Zalewski*
- 448** European Society of Gynaecological Oncology 2019 meeting summaries  
*M A Angeles, A N Strojna, R Pareja, P T Ramirez*

## Cervical Cancer

- 456** Fusion imaging of ultrasound and MRI in the assessment of locally advanced cervical cancer: a prospective study  
*F Moro, B Gui, D Arciuolo, V Bertoldo, R Borzi, P Romeo, F Petta, F Cambi, T Pasciuto, G F Zannoni, V Valentini, R Manfredi, G Scambia, A C Testa*
- 466** Para-aortic lymph node surgical staging in locally-advanced cervical cancer: comparison between robotic versus conventional laparoscopy  
*L Loverix, R R Salih, E Van Nieuwenhuysen, N Concin, S Han, T van Gorp, I Vergote*
- 473** Outcomes analysis of pre-brachytherapy MRI in patients with locally advanced cervical cancer  
*K Murofushi, Y Yoshioka, M Sumi, H Ishikawa, M Oguchi, H Sakurai*

## Uterine Cancer

- 480** Molecular variations in uterine carcinosarcomas identify therapeutic opportunities  
*E Crane, W Naumann, D Tait, R Higgins, T Herzog, J Brown*
- 485** Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus  
*M Onstad, J Ducie, B M Fellman, N R Abu-Rustum, M Leitao, A Mariani, F Multinu, K H Lu, P Soliman*

## Ovarian Cancer

- 491** Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer  
*J R Salinaro, K McQuillen, M Stemple, R Boccaccio, J Ehrisman, A M Lorenzo, L Havrilesky, A A Secord, V Galvan Turner, K N Moore, B Davidson*
- 498** Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer  
*J P Grabowski, C Martinez Vila, R Richter, E Taube, H Plett, E Braicu, J Sehouli*

- 504** Recurrence patterns in patients with abnormal cardiophrenic lymph nodes at ovarian cancer diagnosis

*A Larish, I Mert, M McGree, A Weaver, S Sheedy, W Cilby*

- 509** Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GClG survey (Expression IV)

*I Rohr, S Alavi, R Richter, M Keller, R Chekerov, G Oskay-Özcelik, M Heinrich, C Taskiran, F Joly, R Berger, A du Bois, A Gornjec, I Vergote, P Achimas-Cadariu, D Lorusso, J Maenpaa, J Sehouli*

## Therapeutics

- 515** Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma

*L M Chambers, A Herrmann, C M Michener, C A Ferrando, S Ricci*

- 525** A digital media attention diversion improves mood and fear in patients receiving chemotherapy for recurrent gynecologic malignancies: results of a randomized trial

*R Spencer, V Alexander, J Eickelhoff, K Woo, E Costanzo, N Marx, S Rose*

## Surgery

- 533** Perioperative glycemic measures among non-fasting gynecologic oncology patients receiving carbohydrate loading in an enhanced recovery after surgery (ERAS) protocol

*S Alimena, M Falzone, C M Feltmate, K Prescott, L Contrino Slattery, K Elias*

## Clinical trial

- 541** An exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA study): a randomized controlled pilot trial

*T Maurer, J von Grundherr, S Patra, A Jaeger, H Becher, B Schmalfeldt, B-C Zyriax, J Chang-Claude*

## Case study

- 546** Peritoneal tuberculosis: the great mimicker

*A Varghese, A Fader, M Wilbur, K Salimian, J R Azadi, P T Johnson, R Stone*

## Corners of the world

- 551** Onsite training of clinicians on new techniques to improve cervical cancer prevention in sub-Saharan Africa

*J F Domgue, F Manjuh, K Nulah, T Welty, A Waxman*

## Video articles

- 553** Transvaginal phase of laparoscopic radical hysterectomy

*C Kohler, A Jacob, V Schneider, A Schneider, A Plaikner*

- 555** Laparoscopic laterally extended pelvic resection for gynecological malignancies

*M C Di Donna, G Sozzi, C Cicero, G Vizzielli, G Scambia, V Chiantera*

- 556** Right diaphragmatic peritonectomy for ovarian carcinomatosis in 10 steps

*M A Angeles, C Martínez-Gómez, F Migliorelli, E Chantalat, A Martínez, C Ferron*

- 558** Step-by-step total pelviperitonectomy with modified posterior pelvic exenteration

*A Tejerizo-García, A Olloqui, G Lopez, C Alvarez-Conejo, O Caso-Maestro, A Díez*

## Miscellaneous

- 559** Correction: *A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer*